BRAF and melanoma: Surprisingly, anti-tumor activity was observed not only against human melanomas with B-Raf V600E mutation (due to direct toxicity against these cells), but also against other human tumor types including colon and lung carcinomas, and mouse tumors, regardless of their B-Raf status.